OHSU’s HIV vaccine technology acquired by Bay Area biotech

A San Francisco-based biotech company has acquired vaccine research by Oregon Health & Science University scientists, marking a critical step toward commercialization of a promising HIV vaccine. The deal involves the startup Vir Biotechnology Inc. buying TomegaVax Inc., an OHSU spinoff that holds the rights to the vaccine technology developed by Dr. Louis Picker and Klaus Frueh at OHSU’s Vaccine and Gene Therapy Institute in Beaverton.